Research on the Pathological Mechanisms and Therapeutic Targets of Atrial Cardiomyopathy

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2600117878

Enrollment

Unknown

Registered

2026-01-29

Start date

2026-02-01

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atrial Cardiomyopathy (ACM) and Atrial Fibrillation (AF)

Interventions

Control group:None

Atrial Cardiomyopathy group:None

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for atrial cardiomyopathy as specified in the 2024 EHRA/HRS/APHRS/SOLAECE consensus 2. Patients who have undergone or not undergone cardiac surgery (e.g., atrial fibrillation radiofrequency ablation, cardiac valve replacement, MAZE procedure).

Exclusion criteria

Exclusion criteria: 1.Patients with comorbid severe ischemic heart disease, malignant arrhythmias, myocarditis, congenital heart disease, and other clearly diagnosed cardiomyopathies; 2.Secondary atrial lesions (e.g., hyperthyroidism, alcoholic cardiomyopathy); 3.Active tumors or immune diseases, malignant tumors, severe hepatorenal insufficiency, and autoimmune diseases.

Design outcomes

Primary

Measure	Time frame
The levels of NT-proBNP in peripheral blood and left atrial blood;The levels of interleukin-6 (IL-6) in peripheral blood and left atrial blood;The levels of hs-cTnT in peripheral blood and left atrial blood;The levels of TNF-a in peripheral blood and left atrial blood;	—

Countries

China

Contacts

Public ContactLu Yao

Xuzhou Central Hospital

luyaoyanyan@njmu.edu.cn+86 181 6877 9137

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 7, 2026